HOW CAN I FIND BUSINESS PARTNERS AND BE IN THE KNOW ON INDUSTRY INTELLIGENCE?

    SOCMA’s commercial network helps you find the right connections to develop partnerships with contract manufacturers and customers. We are your bridge to finding suppliers and customers through our lead sheet services, and we are your source of intelligence for end-market insights and product applications. Our ChemSectors network provides the industry intelligence to make key business growth decisions.

    grow your business

    What resources will help me strengthen my operations, train my employees and improve safety?

    Our compliance and stewardship programs promote and guide the implementation of safe, sustainable and environmentally responsible operations across the supply chain.

    discover your resources

    Where can I get intel on the latest regulations and policy specifically impacting specialties?

    We are a powerful industry advocate. Our regulatory and legislative programs ensure you are always at the forefront of any issues or policies that may impact the way you do specialty chemistry.

    find policy solutions

    WHERE CAN I GAIN TARGETED ACCESS TO THE SPECIALTY CHEMICAL INDUSTRY FOR MY TALENT POOL?

    SOCMA’s Career Center is the only one-stop shop for talent management and career resources for the chemical industry. By using the Career Center, your available positions are advertised to a segmented audience in the chemistry space, delivering better candidates and results.

    build your workforce

    IN THE NEWS

    January 14, 2021

    SOCMA Welcomes Three New Member Companies to Begin 2021

    The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of three companies – Valysynthese, Gold Eagle and Forever Pumpkin – to its growing and diverse membership. This brings SOCMA’s total membership to 135 companies to commence 2021.
    Read more
    January 12, 2021

    Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

    Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor’s leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.
    Read more

    UPCOMING EVENTS